Docencia

Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial (05-05-2018)

Dr. Arkaitz Imaz. Servicio de Enfermedades Infecciosas Hospital Universitario de Bellvitge, Barcelona

Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial (16-04-2018)

Dr. Esteban Martínez. Infectious Diseases Unit. Hospital Clínic, University of Barcelona

Disparities in the Quality of Cardiovascular Care Between HIV-Infected Versus HIVUninfected Adults in the United States: A Cross-Sectional Study (02-04-2018)

Dra. Ana Mariño. Unidad de VIH. Hospital Arquitecto Marcide-Novoa Santos, A Coruña.

Non Antiretrocial Polypharmacy and Adverse Health Outcomes Amon HIV. Infected and Uninfected Individuals (15-03-2018)

Dr. Julián Olalla Sierra. Especialista en Medicina Interna Hospital Costa del Sol, Marbella

Efficacy and safety of varenicline for smoking cessation in people living with HIV in France (ANRS 144 Inter-ACTIV): a randomised controlled phase 3 clinical trial (01-03-2018)

Dra. Marta Montero Alonso. Unidad de Enfermedades Infecciosas. Hospital Universitario y Politécnico la Fe, Valencia.

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies (15-02-2018)

Dra. Matilde Sánchez Conde. Infectious Diseases Unit. Hospital Ramón y Cajal, Madrid

Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance ofHIV viral suppression in patients with high cardiovascular (01-02-2018)

Dr. Esteban Martínez. Infectious Diseases Unit. Hospital Clínic, University of Barcelona

HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review andmeta-regression analysis (18-01-2018)

Dr. Arkaitz Imaz. Servicio de Enfermedades Infecciosas Hospital Universitario de Bellvitge, Barcelona

Effect of Immediate Initiation of Antiretroviral Treatment in HIV-Positive Individuals Aged 50 Years or Older (01-01-2018)

Dr. Ana Mariño. Unidad de VIH del Hospital Arquitecto Marcide-Novoa Santos

Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, noninferiority trial (15-12-2017)

Dr. Julián Olalla Sierra. Especialista en Medicina Interna Hospital Costa del Sol, Marbella

Antiretroviral combination use during pregnancy and the risk of major congenital malformations (01-12-2017)

Dra. Marta Montero Alonso. Unidad de Enfermedades Infecciosas Hospital Universitario y Politécnico la Fe, Valencia

Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study (16-11-2017)

Dra. Matilde Sánchez Conde. Infectious Diseases Unit Hospital Ramón y Cajal, Madrid

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of randomised, open-label, phase 2b, non-inferiority trial (02-11-2017)

Dr. Arkaitz Imaz. Infectious Diseases Unit Hospital de Bellvitge, Barcelona

Tolerability of Integrase Inhibitors in a Real-Life Setting (16-10-2017)

Dr. Esteban Martínez. Infectious Diseases Unit Hospital Clínic, University of Barcelona

Epidemiology of autoimmune and inflammatory diseases in a French nationwide HIV cohort (02-10-2017)

Dra. Ana Mariño. Unidad de VIH Hospital Arquitecto Marcide-Novoa Santos

Single Dose Versus 3 Doses of Intramuscular Benzathine Penicillin for Early Syphilis in HIV: A Randomized Clinical Trial (15-06-2017)

Dr. Adrian Currán Atencion sanitaria y hospitalaria Hospital Universitari de la Vall d´Hebron

HIV Infection, Immunosuppression, and Age at Diagnosis of Non-AIDS-Defining Cancers (01-06-2017)

Dr. José Ramón Blanco. Investigador de la Unidad de VIH y Alteraciones Metabólicas Asociadas. Centro de investigación Biomédica de La Rioja

Eradication of HCV and non–liver-related non–AIDS-related events in HIV/HCV coinfection (16-05-2017)

Dra. Marisa Montes. Unidad de enfermedades infecciosas. Hospital Universitario de la Paz

Ischaemic stroke in HIV-infected pa:ents: a case–control study (28-04-2017)

Dr. Javier de la Torre Lima. Servicio de Medicina Interna. Hospital Costa del Sol. Marbella

Página 4 de 71234567

Accesos directos